Wednesday, 16 Jan 2019

You are here

Outcomes of Systemic Sclerosis Hospitalization

A study of inpatient systemic sclerosis (SSc) hospitalizations using the 2012–13 National Inpatient Sample database finds an inpatient mortality rate of 5%, and that infection was the most common cause of SSc hospitalizations and in-hospital death.

Researchers from Pennsylvania calculated rates of hospitalization, in-hospital mortality, LOS and hospital costs from 9731 SSc hospitalizations; a sample from an estimated 48 655 nationwide SSc hospitalizations.

Hospitalized patients were predominantly older (63.2 years), female (82.2%) and Caucasian (71.5%).

Infection was the most common cause for SSc hospitalizations (17.4%) and for those who died (32.7%).

Hospital mortality was also associated with acute renal failure (aOR = 4.3, 95% CI: 3.3, 5.60 and aspiration (aOR= 3.5, 95% CI: 2.5, 4.9).

While the median length of stay (LOS) was 4 days, this was significantly prolonged by pulmonary fibrosis, and myositis, infection, acute renal failure, acute bowel obstruction and aspiration (aOR > 2.0 with P < 0.0001).

Higher cost of hospitalization  was predicted by acute renal failure, acute bowel obstruction, and aspiration.

SSc patients are at risk for significant morbidity and mortality, especially if hospitalized with infection or other complications of SSc.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Early Predictive Factors for Scleroderma Renal Crisis

It has been historically said that risk factors for scleroderma renal crisis (SRC) includes include cold exposure, steroid use, dehydration, rapid progression of skin disease, tendon friction rubs, anti-RNA polymerase III antibodies and pregnancy.  A new study examines risk factor for SRC at the onset and diagnosis in systemic sclerosis patients. 

Best of 2018: Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.

Nailfold Videocapillaroscopy in Dermatomyositis

A study of nailfold videocapillaroscopy (NVC) in patients with idiopathic inflammatory myopathies (IIMs) finds abnormalities in more than half of patients suggesting this could be a useful clinical tool in diagnosing and managing patients with IIM. 

TIF1-Ab in Dermatomyositis Linked to Higher Cancer Risk

Several epidemiological studies have reported that a diagnosis of DM or PM may be associated with increased cancer risk. The association appears stronger for DM than PM. Based on a meta-analysis, DM cancer risk is five times higher than in the general population and twice that compared with PM cancer risk. 

Genetic Diagnosis for Previously Undiagnosed Disorders

The NEJM has reported the NIH's Undiagnosed Diseases Network (UDN) study results of genetically identifying new diseases from prospectively followed persons with undiagnosed disorders. The UDN was formed in 2014 as a network of seven clinical sites, two sequencing cores, a coordinating center, central biorepository, a metabolomics core, and a model organisms screening center. It was established to apply a multidisciplinary model in the evaluation of the most challenging cases and to identify the biologic characteristics of newly discovered diseases.